TLR-MD2-fusion protein for the treatment of infectious diseases, chronic inflammatory diseases and sepsis
The recombinant TLR-MD-2 fusion protein or a fusion protein homopolymer / heteropolymer complex can be used for the prophylactic and/or therapeutic treatment of allergic reactions, infections diseases and inflammatory conditions, such as sepsis.
Further Information: PDF
Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
Phone: +49 (0)89/1205-6000
Contact
Dr. Wolfgang Knappe
Media Contact
All latest news from the category: Technology Offerings
Newest articles
State-wide center for quantum science
Karlsruhe Institute of Technology joins IQST as a new partner. The mission of IQST is to further our understanding of nature and develop innovative technologies based on quantum science by…
Newly designed nanomaterial shows promise as antimicrobial agent
Rice scientists develop nanocrystals that kill bacteria under visible light. Newly developed halide perovskite nanocrystals (HPNCs) show potential as antimicrobial agents that are stable, effective and easy to produce. After…
Nanorobot hand made of DNA grabs viruses
…for diagnostics and blocks cell entry. A tiny, four-fingered “hand” folded from a single piece of DNA can pick up the virus that causes COVID-19 for highly sensitive rapid detection…